Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review
BackgroundPityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient’s quality of life and is considered one of the intractable diseases in dermatology. Currently, no satisf...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1544197/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850036600801591296 |
|---|---|
| author | Xiaofang Zhang Kebo Wei Hongxia Song Xi Chen Jiao Yang Jianmei Zhao Yugu Jiang Xin He |
| author_facet | Xiaofang Zhang Kebo Wei Hongxia Song Xi Chen Jiao Yang Jianmei Zhao Yugu Jiang Xin He |
| author_sort | Xiaofang Zhang |
| collection | DOAJ |
| description | BackgroundPityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient’s quality of life and is considered one of the intractable diseases in dermatology. Currently, no satisfactory clinical treatment options are available for this condition, presenting a considerable challenge for dermatologists. We conducted this systematic evaluation to assess the therapeutic potential of existing small molecule drugs for this disease.ObjectivesTo conduct a systematic review of the existing literature on the use of small molecule drugs for treating pityriasis rubra pilaris and to evaluate their clinical effectiveness and safety.MethodsWe conducted a systematic review of all the literature on small molecule drugs for the treatment of Pityriasis rubra pilaris and searched several databases until November 2024, including PubMed, Embase, Web of Science, and the Cochrane Library.ResultsA total of 16 patients with pityriasis rubra pilaris from 11 publications were included. The small molecule drugs, including apremilast, upadacitinib, abrocitinib, and tofacitinib, demonstrate good efficacy and safety in the treatment of pityriasis rubra pilaris across all ages, particularly in patients who have failed systemic therapy and have a poor response to biological agents. However, the conclusions are limited by the small sample size and need to be further confirmed through large-scale randomized controlled clinical trials.ConclusionSmall molecule drugs demonstrate favorable clinical efficacy and safety in the treatment of refractory pityriasis rubra pilaris, exhibiting a relatively rapid onset and a high safety profile. However, the findings in the literature may be affected by publication bias. |
| format | Article |
| id | doaj-art-3e10c23fc9784e9091aa96c4fe0b4f00 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-3e10c23fc9784e9091aa96c4fe0b4f002025-08-20T02:57:05ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-02-011210.3389/fmed.2025.15441971544197Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic reviewXiaofang Zhang0Kebo Wei1Hongxia Song2Xi Chen3Jiao Yang4Jianmei Zhao5Yugu Jiang6Xin He7Department of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, ChinaDepartment of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, ChinaDepartment of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, ChinaDepartment of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, ChinaDepartment of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, ChinaDepartment of Dermatology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, ChinaDepartment of Dermatology, Hospital of Chengdu University of TCM, Chengdu, Sichuan, ChinaDepartment of Dermatology, Chengdu Integrated TCM and Western Medicine Hospital, Chengdu, Sichuan, ChinaBackgroundPityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient’s quality of life and is considered one of the intractable diseases in dermatology. Currently, no satisfactory clinical treatment options are available for this condition, presenting a considerable challenge for dermatologists. We conducted this systematic evaluation to assess the therapeutic potential of existing small molecule drugs for this disease.ObjectivesTo conduct a systematic review of the existing literature on the use of small molecule drugs for treating pityriasis rubra pilaris and to evaluate their clinical effectiveness and safety.MethodsWe conducted a systematic review of all the literature on small molecule drugs for the treatment of Pityriasis rubra pilaris and searched several databases until November 2024, including PubMed, Embase, Web of Science, and the Cochrane Library.ResultsA total of 16 patients with pityriasis rubra pilaris from 11 publications were included. The small molecule drugs, including apremilast, upadacitinib, abrocitinib, and tofacitinib, demonstrate good efficacy and safety in the treatment of pityriasis rubra pilaris across all ages, particularly in patients who have failed systemic therapy and have a poor response to biological agents. However, the conclusions are limited by the small sample size and need to be further confirmed through large-scale randomized controlled clinical trials.ConclusionSmall molecule drugs demonstrate favorable clinical efficacy and safety in the treatment of refractory pityriasis rubra pilaris, exhibiting a relatively rapid onset and a high safety profile. However, the findings in the literature may be affected by publication bias.https://www.frontiersin.org/articles/10.3389/fmed.2025.1544197/fullpityriasis rubra pilarissystematic reviewsmall molecule drugsefficacy and safetJanus kinase (JAK) inhibitorsPDE-4 inhibitor |
| spellingShingle | Xiaofang Zhang Kebo Wei Hongxia Song Xi Chen Jiao Yang Jianmei Zhao Yugu Jiang Xin He Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review Frontiers in Medicine pityriasis rubra pilaris systematic review small molecule drugs efficacy and safet Janus kinase (JAK) inhibitors PDE-4 inhibitor |
| title | Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review |
| title_full | Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review |
| title_fullStr | Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review |
| title_full_unstemmed | Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review |
| title_short | Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review |
| title_sort | efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris a systematic review |
| topic | pityriasis rubra pilaris systematic review small molecule drugs efficacy and safet Janus kinase (JAK) inhibitors PDE-4 inhibitor |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1544197/full |
| work_keys_str_mv | AT xiaofangzhang efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT kebowei efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT hongxiasong efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT xichen efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT jiaoyang efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT jianmeizhao efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT yugujiang efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview AT xinhe efficacyandsafetyofsmallmoleculedrugsinthetreatmentofpityriasisrubrapilarisasystematicreview |